(VIANEWS) – Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) fell by a staggering 24.42% in 10 sessions from $20.31 at 2023-01-19, to $15.35 at 11:14 EST on Thursday, after two consecutive sessions in a row of losses. NASDAQ is rising 1.95% to $12,046.50, after two successive sessions in a row of gains.
Catalyst Pharmaceuticals’s last close was $15.31, 30.76% under its 52-week high of $22.11.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.71.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 21.62. Meaning,
the purchaser of the share is investing $21.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.35%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 122.2% and 166.7%, respectively.
More news about Catalyst Pharmaceuticals (CPRX).
